108985
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
基于靶向工程纳米粒子的呼吸系统疾病治疗药物的进展：当前见解与未来展望
Authors Chai B, Li Y , Wang Y, Yang D, Zhang L
Received 13 May 2025
Accepted for publication 14 October 2025
Published 22 October 2025 Volume 2025:20 Pages 12831—12857
DOI https://doi.org/10.2147/IJN.S539908
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Sachin Mali
Baiquan Chai,1,* Yuhan Li,2,* Yulong Wang,2,* Danlei Yang,1 Lei Zhang1
1Department of Pulmonary and Critical Care Medicine, NHC Key Laboratory of Respiratory Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China; 2First Clinical College, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Lei Zhang, Department of Pulmonary and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China, Tel +86-27-83665522, Email zhl930223@qq.com Danlei Yang, Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China, Tel +86-27-83665522, Email yangdanlei@126.com
Abstract: Treatments for respiratory diseases, including lung cancer, infectious pulmonary disease, acute respiratory distress syndrome (ARDS) and pulmonary fibrosis remain challenging. Conventional therapy such as inhaled corticosteroids and systemic antibiotics faces limitations of poor bioavailability, nonspecific biodistribution, and inadequate pulmonary barrier penetration, which often lead to suboptimal therapeutic outcomes. Engineered nanoparticles (ENPs) have recently gained significant attention as a potential solution to address these existing challenges. By encapsulating therapeutic agents within lipid-based, polymeric, or inorganic nanostructures, ENPs enable targeted delivery and controlled release, thereby minimizing systemic toxicity and increasing interactions with disease-specific cellular targets. Notably, inhalable ENPs targeting lung cancer cell receptors have demonstrated exceptional ability to penetrate lung barriers, evade clearance, and deliver drugs deep into lung tissue while significantly reducing systemic side effects. Recent advancements in nanotechnology have further broadened their applications in gene therapy, immune modulation and regenerative medicine, such as stem cell-derived extracellular vesicles (EVs) and hydrogel scaffolds for pulmonary tissue repair. This review elucidates therapeutic applications in respiratory diseases, summarizes current advances in formulation design, and discusses translational challenges including nanoparticle heterogeneity, inhalation barriers and gaps in clinical implementation such as reproducibility and scalability, and future directions for clinical translation including reproducibility.
Keywords: respiratory diseases, engineered nanoparticles, nanomedicine, drug delivery systems, targeted therapy, regenerative medicine, clinical translation
1Department of Pulmonary and Critical Care Medicine, NHC Key Laboratory of Respiratory Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China; 2First Clinical College, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Lei Zhang, Department of Pulmonary and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China, Tel +86-27-83665522, Email zhl930223@qq.com Danlei Yang, Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China, Tel +86-27-83665522, Email yangdanlei@126.com
Abstract: Treatments for respiratory diseases, including lung cancer, infectious pulmonary disease, acute respiratory distress syndrome (ARDS) and pulmonary fibrosis remain challenging. Conventional therapy such as inhaled corticosteroids and systemic antibiotics faces limitations of poor bioavailability, nonspecific biodistribution, and inadequate pulmonary barrier penetration, which often lead to suboptimal therapeutic outcomes. Engineered nanoparticles (ENPs) have recently gained significant attention as a potential solution to address these existing challenges. By encapsulating therapeutic agents within lipid-based, polymeric, or inorganic nanostructures, ENPs enable targeted delivery and controlled release, thereby minimizing systemic toxicity and increasing interactions with disease-specific cellular targets. Notably, inhalable ENPs targeting lung cancer cell receptors have demonstrated exceptional ability to penetrate lung barriers, evade clearance, and deliver drugs deep into lung tissue while significantly reducing systemic side effects. Recent advancements in nanotechnology have further broadened their applications in gene therapy, immune modulation and regenerative medicine, such as stem cell-derived extracellular vesicles (EVs) and hydrogel scaffolds for pulmonary tissue repair. This review elucidates therapeutic applications in respiratory diseases, summarizes current advances in formulation design, and discusses translational challenges including nanoparticle heterogeneity, inhalation barriers and gaps in clinical implementation such as reproducibility and scalability, and future directions for clinical translation including reproducibility.
Keywords: respiratory diseases, engineered nanoparticles, nanomedicine, drug delivery systems, targeted therapy, regenerative medicine, clinical translation